Cholecystokinin-B (CCK-B) receptor antagonists improve 'aged' sleep: A new class of sleep modulators?

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 21, Issue 1, 1999, Pages 31-38

  Crespi, Francesco ^a  

^a GSK   (Italy)

Author keywords

Cholecystokinin (CCK) receptor antagonism; Electroencephalograph (EEG); Rat; Sleep

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; BENZODIAZEPINE DERIVATIVE; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DEVAZEPIDE; GV 150013; HYPNOTIC SEDATIVE AGENT; TRIAZOLAM; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE CALCULATION; DRUG EFFECT; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; REM SLEEP; SLEEP DISORDER; SLEEP PATTERN; SLEEP TIME;

EID: 0032914390     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1999.21.1.527016     Document Type: Article

References (45)

1. Shapiro, C.M., Dement, W.C. ABC of sleep disorders. Impact and epidemiology of sleep disorders. BMJ 1994, 306: 1604-7.
2. Sleep in America, a National Survey of US Adults. Houston, Gallup Organization Inc, 1991.
3. Waterhouse, J. ABC of sleep disorders. Circadian rhythms. BMJ. 1994, 306: 448-51.
4. Swift, C.G., Shapiro, C.M. ABC of sleep disorders. Sleep and sleep problems in elderly people. BMJ 1994, 306: 1468-71.
5. Mendelson, W. Pharmacotherapy of insomnia. Psychiatric Clin of North America 1987, 10: 555-63.
6. Takaki, K., Watson, B. Agents for the treatment of sleep disorders. Exp Opin Ther Patents 1994, 4: 1243-52.
7. Kapas, L., Obal, F.J.R., Alfoldi, P., Rubcsek, G., Penke, B., Obal, F. Effect of nocturnal I.P. administration of CCK in rats, simultaneous increase in sleep increase in EEG slow wave activity, reduction of motor activity suppression of eating and decrease in brain temperature. Brain Res 1988, 438: 155-64.
8. Kapas, L., Obal, F. J.R., Opp, M.R., Johannsen, L., Krueger, J.M. Intraperitoneal injection of CCK elicits sleep in rabbits. Physiol Behav 1991, 50: 1241-44.
9. Kapas, L. CCK-induced sleep is suppressed by LY-288,513, a CCK-B receptor antagonist. J Sleep Res 1996, 5(Suppl. 1): 103, No. 205.
10. De Saint Hilaire, Z., Roques, B.P., Nicolaidis, S. Effect of a highly selective central CCK-B receptor agonist BC-264 on rat sleep. Pharmacol Biochem Behav 1991, 38: 545-8.
11. Bennet, L., Johnston, B.M., Gluckman, P.D. Apneic effect of CCK in unanesthetized fetal sheep. J Dev Physiol 1990, 14: 229-33.
12. Jouvet, M. Recherches sur les structures nerveuses et les mechanismes responsables des phases du sommeil physiologique. Arch Ital Biol 1962, 100: 125-206.
13. Mouret, J., Renaud, B., Quentin, P., Michel, D., Schott, B. Monoamines et regulation de la vigilance I: Apport et interpretation biochimique des donnees polygraphiques. Revue Neurologique 1972, 127: 139-55.
14. Rechtschaffen, A., Kales, A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. UCLA Brain Information Service/Brain Res Institute, 1968.
15. Lotti, V.J. In vivo pharmacology of devazepide, a new potent nonpeptide peripheral CCK antagonist. J Pharmacol Exp Ther 1987, 241: 103-9.
16. Reggiani, A., Gerrard, P., Maraia, G., Melotto, S., Ratti, E., Gaviraghi, G., Trist, D.G. Anxiolytic activity of GV 150013, a new potent and selective CCK-B antagonist. Br J Pharmacol 1995, 114: 92P.
17. Stone, W. Sleep and aging in animals. Relationship with circadian rhythms and memory. Clin Geriatr Med 1989, 5: 363-79.
18. Bixler, E., Kales, A., Jacoby J. Nocturnal sleep and wakefulness: Effects of age and sex in normal sleepers. Int J Neurosci 1984, 23: 33-42.
19. Van Gool, W., Mirmiran, M. Age related changes in the sleep pattern of male adult rats. Brain Res 1983, 279: 394-8.
20. Deportere, H., Decobert, M., Riou, F. Hypnotics: Clinical value of pharmaco-EEG methods. Neuropsychobiology 1986, 16: 157-62.
21. Crawley, J., Corwin, R. Biological action of CCK. Peptides 1994, 15: 731-55.
22. Jouvet, M., Buda, M., Crespi, F. Hypnogenic effects of some peptides. In: Clinical Neuropharmacology. Bunney, Costa, Potkin (Eds.). Raven Press: New York 1986, 465-7.
23. 3 receptor antagonists of release of CCK-like immunoreactivity from the frontal cortex of freely-moving rats. Naunyn Schmiedeberg's Arch Pharmacol 1993, 347: 111-14.
24. Mendelson, W., Canin, M., Cook, J. A BDZ receptor antagonist decreases sleep and reverses the hypnotic actions of flurazepam. Science 1983, 219: 414-6.
25. Scherschlicht, R. Role for GABA in the control of the sleep-waking cycle. In: Sleep, Neurotransmitters and Neuromodulators 1985. Wauquier Gaillard and Monti (Eds.). Raven Press: New York 1985, 237-49.
26. Rakovska, A. CCK-GABA interactions in rat striatum. Neuropeptides 1995, 29: 257-62.
27. Demesquita, S., Haney, W.H. Effect of chronic icv infusion of CCK on respiration and sleep. Brain Res 1986, 378: 127-32.
28. De Saint Hilaire-Kafi, Z., Deportere, H., Nicolaidis, S. Does CCK induce physiological satiety and sleep. Brain Res 1989, 488: 304-10.
29. Harro, J., Westerling, P., Oreland, L. CCK-B receptor activation reduces glutamate-induced depolarization in slices of cerebral cortex. J Neural Transmission-General Section 1993, 93: 61-6.
30. Tamura, Y., Salo, Y., Akaike, A., Shiomi, H. Mechanisms of CCK-induced protection of cultured cortical neurons against NMDA receptor-mediated glutamate toxicity. Brain Res 1992, 592: 217-325.
31. Collingridge, G.L., Singer, W. Excitatory amino acid receptors and synoptic plasticity. Trends Pharmacol Sci 1990, 11: 290-6.
32. Dzoljic, M.R., De Vries, R. NO Synthase inhibition reduces wakefulness. Neuropharmacology 1994, 33: 1505-9.
33. Kapas, L., Fang, J., Krueger, J.M. Inhibition of NO synthesis inhibits rat sleep. Brain Res 1994, 664: 189-96.
34. Koella, W. Role of neurotransmitters in sleep organization. Therapiewoche 1985, 35: 1646-59.
35. Kovacevic, R., Radulovacky, M. Monoamine changes in the brain of cats during SWS. Science 1976, 193: 1025-27.
36. Hill, D.R., Campbell, N.J., Shaw, T.M., Woodruff, G.N. Autoradiographic localisation and biochemical characterisation of peripheral type CCK receptors in rat CNS using highly selective non peptide CCK antagonists. J Neurosci 1987, 7: 2967-77.
37. Hill, D.R., Shaw, T.M., Graham, W., Woodruff, G.N. Autoradiographical detection of CCK-A receptors in primate brain using 1251-Bolton hunter CCK8 and 3H-MK 329. J Neurosci 1990, 10: 1070-81.
38. Altar, C.A., Boyer, W.C. Brain CCK-B receptors mediated the suppression of dopamine release by CCK. Brain Res 1989, 483: 321-26.
39. Schade, R., Vick, K., Sohr, R., Ott, T., Lemmer, B. Correlative circadian rhythms of CCK and DA content in nucleus accumbens and striatum of rat brain. Behav Brain Res 1993, 59: 211-14.
40. Meyer, D.K., Strauss, J. DA modulates CCK release in neostriatum. Nature 1983, 301: 338-40.
41. Rasmussen, K., Czachura, J.F., Stockton, M.E., Howbert, J.J. Electrophysiological effects of CCK-B and CCK-A antagonists on midbrain DA neurons. J Pharmacol Exp Ther 1993, 264: 480-8.
42. Edgar, D., Seidel, W., Dement, W. Triazolam-induced sleep in the rat: influence of prior sleep, circadian time, and light/dark cycles. Psychopharmacology 1991, 105: 374-80.
43. Gandolfo, G., Scherschlicht, R., Gottesmann, C. Benzodiazepines promote the intermediate stage at the expense of paradoxical sleep in rats. Pharmacol Biochem Behav 1994, 49: 921-7.
44. Lobo, B.L., Greene, W.L. Zolpidem: Distinct from triazolam? Annals Pharmacotherapy 1997, 31: 625-32.
45. Cassone, V. Effect of melatonin on vertebrate circadian systems. TINS 1990, 13: 457-63.